pharma
dog
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
News
when
Latest
Archive
by source
All Sources
Sources Page
◐
Sign In
Subscribe
🐶
home
jobs
news
search
the cabinet
Drugs
8,127
products tracked ·
1,561
matching
★ save view
↓
export CSV
search
phase
all
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
sort
catalysts
recent
name
therapeutic area
all
Oncology
1831
Infectious Disease
718
Cardiology
425
Pulmonology
396
Immunology
371
Ophthalmology
368
Dermatology
300
Women's Health
view
list
cards
Phase 2
durvalumab + IPH-5201
Non-Small Cell Lung Cancer
$AZN
ASTRAZENECA PLC
0
catalysts
Phase 2
dutogliptin tartrate
Post-Myocardial Infarction
Recardio Inc
0
catalysts
Phase 2
duvalgagene otiparvovec
Fabry Disease
$FDMT
4D Molecular Therapeutics, Inc.
0
catalysts
Phase 2
← prev
page 37 of 53
next →
131
Pain
89
Neurology
1
efarindodekin alfa
efarindodekin alfa[INN]
Cervical Cancer
$GILD
GILEAD SCIENCES, INC.
0
catalysts
Phase 2
efdoralprin alfa
efdoralprin alfa [INN]
Alpha-1 Antitrypsin Deficiency (A1AD)
$SNY
Sanofi
0
catalysts
Phase 2
efgitasialase alfa
Breast Cancer
Palleon Pharmaceuticals Inc
0
catalysts
Phase 2
efineptakin alfa
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
NeoImmuneTech Inc
0
catalysts
Phase 2
efinopegdutide
Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH)
Glucagon receptor
Glucagon-like peptide 1 receptor
$MRK
Merck & Co., Inc.
0
catalysts
Phase 2
efocipegtrutide
efocipegtrutide [INN]
Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH)
Hanmi Pharmaceuticals Co Ltd
0
catalysts
Phase 2
efpegerglucagon
efpegerglucagon [INN]
Hyperinsulinemia
Hanmi Pharmaceuticals Co Ltd
0
catalysts
Phase 2
efzofitimod
efzofitimod [INN]
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)
$ATYR
aTYR PHARMA INC
0
catalysts
Phase 2
egalognastat
egalognastat [INN]
Progressive Supranuclear Palsy
Grupo Ferrer Internacional SA
0
catalysts
Phase 2
elecoglipron
Type 2 Diabetes
$AZN
ASTRAZENECA PLC
0
catalysts
Phase 2
elezanumab
Traumatic Spinal Cord Injury
Repulsive guidance molecule A
$ABBV
AbbVie Inc.
0
catalysts
Phase 2
elifactant
Neonatal Respiratory Distress Syndrome
Chiesi Farmaceutici SpA
0
catalysts
Phase 2
elironrasib
Non-Small Cell Lung Cancer
$RVMD
Revolution Medicines, Inc.
0
catalysts
Phase 2
elisrasib
elisrasib [INN]
Solid Tumor
D3 Bio Inc
0
catalysts
Phase 2
elraglusib
Neuroblastoma
Glycogen synthase kinase-3 beta
$ACTU
ACTUATE THERAPEUTICS, INC.
0
catalysts
Phase 2
eltivutabart
eltivutabart [INN]
Pancreatic Ductal Adenocarcinoma
Trishula Therapeutics Inc
0
catalysts
Phase 2
elunetirom
Bipolar I Disorder
Autobahn Therapeutics Inc
0
catalysts
Phase 2
elzovantinib
Non-Small Cell Lung Cancer
Bristol-Myers Squibb Co
0
catalysts
Phase 2
emicizumab
Hemlibra (emicizumab-kxwh)
Acquired Hemophilia A
Coagulation factor IX and X
Chugai Pharmaceutical Co Ltd
0
catalysts
Phase 2
emodepside
Onchocerciasis (River Blindness)
Bayer AG
0
catalysts
Phase 2
emraclidine
Psychosis
$ABBV
AbbVie Inc.
0
catalysts
Phase 2
emrusolmin
emrusolmin [INN]
Multiple System Atrophy (Multi-System Degeneration)
$TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
0
catalysts
Phase 2
emugrobart
emugrobart [INN]
Obesity
F. Hoffmann-La Roche Ltd
0
catalysts
Phase 2
enamptcumab
eNamptor
Acute Respiratory Distress Syndrome
Aqualung Therapeutics Corp
0
catalysts
Phase 2
encoberminogene rezmadenovec
Refractory Angina
XyloCor Therapeutics Inc
0
catalysts
Phase 2
endoxifen
Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast…
$ATOS
ATOSSA THERAPEUTICS, INC.
0
catalysts
Phase 2
enekinragene inzadenovec
Osteoarthritis
$PCRX
Pacira BioSciences, Inc.
0
catalysts
